Creating targeted delivery methods for beta cell therapies in diabetes
Development of platforms for beta cell-specific delivery and ligand discovery
This study is exploring new ways to help people with type 1 diabetes by finding better methods to deliver treatments directly to the insulin-producing cells in the pancreas, which could lead to more effective and lasting solutions for managing their condition.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Broad Institute, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-10871834 on NIH RePORTER |
What this research studies
This research focuses on improving treatments for patients with type 1 diabetes by developing new methods to deliver therapies specifically to beta cells in the pancreas. Current treatments rely on insulin injections and islet transplants, which have significant limitations, including donor scarcity and immune rejection. The research aims to use chemical biology techniques to enhance the proliferation of beta cells, potentially leading to more effective and long-lasting therapies. By targeting the release of therapeutic agents directly to beta cells, the hope is to improve patient outcomes and reduce the need for insulin dependence.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with type 1 diabetes who may benefit from improved beta cell function.
Not a fit: Patients with type 2 diabetes or those who do not have a functioning pancreas may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for type 1 diabetes, reducing the need for insulin therapy and improving patients' quality of life.
How similar studies have performed: While the approach of targeting beta cell therapies is innovative, similar research has shown promise in enhancing beta cell function and proliferation.
Where this research is happening
Cambridge, United States
- Broad Institute, INC. — Cambridge, United States (Active)
Researchers
- Principal investigator: Choudhary, Amit — Broad Institute, INC.
- Study coordinator: Choudhary, Amit
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.